Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials.

Robert J. Holt,David R. Micklem,Anthony Brown,Murray Yule,Sonja Loges,James B. Lorens

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials.

2018

Robert J. Holt
David R. Micklem
Anthony Brown
Murray Yule
Sonja Loges
James B. Lorens

2559Background: AXL expression is strongly associated with immunosuppression and therapy resistance in a wide range of cancers. Bemcentinib is a first-in-class, orally bioavailable, selective AXL T...

Keywords:

Pharmacodynamics
Phases of clinical research
Biomarker (medicine)
Pathology
Cancer research
Medicine
Oncology
Immunosuppression
Internal medicine
treatment resistance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations